Exciton Technologies Inc., creator of the patented infection-fighting Silver Oxysalts technology, has made a pivotal turn to profitability through expansion of its license agreement with Crawford Healthcare Ltd., the UK's fastest growing wound care company. Exciton has been working with Crawford since 2013 but, following what Crawford calls "a dramatic market response to the use of this patented technology in both the US and the UK," the companies have now expanded to an exclusive global arrangement for a broader range of products. Commenting on the deal, Crawford's Healthcare CEO, Richard Anderson said, "We now have an unrivalled antimicrobial platform to tackle the issue of secondary infections faced by clinicians the world over."

Read full news press release: Expands Global Licensing Agreement and Manufacturing Facilities  March 8, 2016

cover image SD7


Subscribe for Updates

* indicates required